MW-032 is under clinical development by Mabwell Shanghai Bioscience and currently in Phase III for Bone Metastasis. According to GlobalData, Phase III drugs for Bone Metastasis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MW-032’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MW-032 overview

Denosumab biosimilar is under development for the treatment of bone metastases from breast cancer. It is a recombinant human monoclonal antibody, administered by the subcutaneous route. The therapeutic candidate acts by targeting the receptor activator of nuclear factor kappa B ligand (RANKL). 

Mabwell Shanghai Bioscience overview

Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.

For a complete picture of MW-032’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.